Takeda, Y., Kobayashi, K., Akivama, Y., Soma, T., Handa, S., Kudoh, S., & Kudo, K. (2001). Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients. International Journal of Cancer, 92(2), 269–275.doi: 10.1002/1097-0215(200102)9999:9999<::AID-IJC1179>3.0.CO;2-3
To evaluate the use of oral alkalization (OA) with control of defecation (CD)
The study was conducted at a single institution.
This was a case-control study.
Patient response rates did not indicate that OA and CD compromised the clinical efficacy of irinotecan and cisplatin therapy. Although a reduced amount of irinotecan and SN-38 may be circulated enterohepatically, the increased dose intensity conferred by OA and CD resulted in maintenance of the same degree of clinical efficacy.
OA and CD appeared to be useful in preventing the dose-limiting side effects of irinotecan, primarily nausea, vomiting, granulocytopenia, and delayed diarrhea.